AstraZeneca plc vs VanEck Australian Floating Rate ETF — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while VanEck Australian Floating Rate ETF trades at $50.94. The key difference: AstraZeneca plc pays a 2.01% dividend while VanEck Australian Floating Rate ETF pays none, and VanEck Australian Floating Rate ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | FLOT | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $209.48 | $51.09 |
52-Week Low | $147.06 | $50.72 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
FLOT trades at $50.93 with minimal daily movement (+0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The ETF maintains consistent dividend payments with recent distributions of $0.17-$0.18. Market focus remains on Federal Reserve policy decisions and their impact on floating rate bonds amid persistent inflation concerns.
FLOT offers exposure to high-quality floating rate bonds with a 4.0% SEC yield, positioned as a conservative income vehicle. The ETF benefits from potential Fed rate hikes but faces headwinds from inflation volatility and Treasury yield fluctuations. Current technical weakness suggests cautious near-term positioning despite the defensive characteristics of floating rate securities.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →